Prostate cancer is the most common cancer in men, with more than 40,000 new cases diagnosed in England each year. When prostate cancer is caught early enough, radiotherapy can be a highly effective treatment, with high-energy X-rays targeted at the prostate, killing cancer cells and preventing them from spreading.
However, the radiation is not absorbed by the prostate, meaning that nearby healthy organs can be affected. SpaceOAR hydrogel acts as a spacer, reducing the amount of radiation that can pass through the prostate and damage the rectum during treatment, by temporarily positioning it away from the high dose radiation used in treatment.
Dr Sam Roberts, director of innovation and life sciences for NHS England, confirmed that the programme has been “amazingly successful at getting new innovations to patients, with over 300,000 patients benefitting from previous innovations, and this year we have another great selection of proven innovations.”
He continued, “We will build on this success with our commitments set out in the Long Term Plan, to support innovators and the NHS to remove barriers to uptake so patients can benefit faster.”